Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... previously conducted three FDA approved Phase 1 clinical trials, including two cancer trials, and Aduro will expand upon these programs in its future clinical studies. ... grants and contracts from the Department of Defense for development of a therapeutic vaccine for Hepatitis C, and from the National Institute of Allergy and Infectious Diseases (via ...
2009 NOV 23 ... further confirmatory data on PROSTVAC™, the company's late-stage prostate cancer vaccine candidate. Oral presentations were held at several cancer congresses, including ASCO and ...
2009 NOV 23 ... which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a treatment for hospitalized H1N1 patients using it's ... in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology. The data was presented at the 7th GTCbio Vaccine: "All Things Considered" ...
2009 NOV 23 ... factor receptor (TGF-R) or TGF targeting molecules for tissue healing or treatment of cancer and fibrotic diseases of lung, skin or kidney as of November 2009. Purchase of the ... Most of the molecules are biologics (antibodies, proteins, peptides, antisense, vaccine, cells). The most advanced projects are in phase III development. Keywords: ...
2009 NOV 24 ... For additional information, contact I.M. Longini, Fred Hutchinson Cancer Research Center, Center Statistics & Quantitat Infectious Disease, Seattle, WA 98109, ... 2009," wrote Y. Yang and colleagues. The researchers concluded: "If a vaccine were available soon enough, vaccination of children, followed by adults, reaching 70% ...
2009 NOV 23 ... States, "Immunotherapeutic vaccine is potentially an effective strategy to combat cancer. Essential components of an effective vaccine must include antigens that are processed ...
2009 NOV 23 ... 530 Walnut St., Philadelphia, PA 19106-3621, USA. Keywords: Country:France, Cancer Vaccines, Anticancer Therapy, Antitumor Activity, Biotechnology, Escherichia coli, ... with a ''real'' turner antigen and that the adjuvant properties of the E. coli-LLO vaccine can be exploited in conjunction with peptides," wrote M.S. Dai and colleagues, INSERM. ...
2009 NOV 23 ... becoming the new partner. The research progress of its Slavica Bio Chem subsidiary, Cancer Mind Up project and its www.mindupbioresearch.com website which the company will launch ... management foresees with the upcoming Novartis acquisition of 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co, thus by default Novaris becoming the ...
2009 NOV 23 ... and Affiliate Investigator of the Clinical Research Division of the Fred Hutchinson Cancer Research Center, will serve as program director and Principal Investigator to direct the ... Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of ...
2009 NOV 23 ... According to recent research from the United States, "Cancer is an age-related disease, and with the graying of the society there is an increasing ... is an increasing need to optimize cancer management and therapy to elderly patients. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, ...
2009 NOV 23 ... are discussed in a new report. According to a study from the United States, "Cancer-derived heat shock protein gp96 induces a tumor-specific protective immune response ... a cell culture-based signaling mechanism." "When used as an extraneous vaccine, one critical interaction which must occur for an immune response to be generated is the ...
2009 NOV 23 ... Treg cells and improve the generation of therapeutic immune responses in patients with cancer. Journal of Immunology, 2009, 183:3682-3689." Petrausch and colleagues ... (Treg) cells represent a major roadblock to the induction of antitumor immunity through vaccine approaches. TGF-beta is a cytokine implicated in the generation and maintenance of Treg ...
2009 NOV 23 ... 1972; Adkins and Riley In: Mech Ageing Dev 103:147-164, 1998; Ben-Yehuda and Weksler In: Cancer Investigation 10:525-531, 1992]. One of the more interesting examples of the functional ... neutralizing antibody response to the yearly multivalent particle inactivated influenza vaccine is less than 20% [Jefferson et al. In: Lancet 264:1165-1174, 2005; Goodwin et al. In: ...
2009 NOV 23 ... in Clinical and Vaccine Immunology (Improvement of a Dendritic Cell-Based Therapeutic Cancer Vaccine with Components of Toxoplasma gondii. Clinical and Vaccine Immunology, ...
2009 NOV 23 ... Additional information can be obtained by contacting M.E. Dudley, National Cancer Institute, Surgery Branch, National Institutes of Health, CRC 3-5752, 10 Center Dr., ... tumor infiltrating lymphocytes administered together with a highly immunogenic fowlpox vaccine expressing a gp100: 209-217 (210M) epitope," scientists writing in the Journal of ...
2009 NOV 23 ... and colleagues published the results of their research in the Journal of the National Cancer Institute (Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A ... whether prevention of hepatocellular carcinoma by the universal Taiwanese HBV vaccine program, launched in July 1984, has extended beyond childhood and to identify the ...
2009 NOV 23 ... 42 months post vaccination." Kjaer and colleagues published their study in Cancer Prevention Research (A Pooled Analysis of Continued Prophylactic Efficacy of ... "Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and ...
2009 NOV 17 ... the wellness benefit include colonoscopy, mammography, Pap smear, PSA test for prostate cancer, serum cholesterol test, among others. "The wellness benefit that ... has enhanced the wellness benefit of its critical illness products by adding the H1N1 vaccine to the list of qualifying procedures. "Employee absence, even in the best ...
2009 NOV 23 ... will help to better control the spread of this virus. Keywords: Cervical Cancer Screening, Health, Infectious Diseases, Medical Supplies, General Health, Managed Care, ... rapid growth based upon more market awareness after the introduction of the HPV vaccine, Gardasil®, which was developed by Merck & Co. (NYSE: MRK). The ...
